Acute myeloid leukemia (AML) is a heterogeneous disorder in which clinical outcomes are determined predominantly by patient age, karyotype, and genomic features. 1 Historically, much of this ...

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) The study planned to randomly assign 300 ...

Asian patients with newly diagnosed acute myeloid leukemia (AML) may have superior overall survival (OS) outcomes compared with White patients, though further data are needed to corroborate this ...

—According to researchers in Germany, the presence of additional cytogenetic or molecular markers included in current risk stratification systems, rather than the presence or absence of a trisomy 8, ...

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease ...

The ELN 2024 framework offers better stratification for AP/BP MPN, but gaps remain between intermediate and adverse groups. The study analyzed 211 patients, showing modest response rates and ...

Subjects with CAG had a significantly lower response to combination therapy OGM provided high resolution and sensitivity in detecting these catastrophic chromosomal events, reinforcing its potential ...

Bionano announced a significant study published in the American Journal of Hematology demonstrating the utility of optical genome mapping (OGM) in detecting structural variants associated with ...

COLUMBUS, Ohio – Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) led a global study ...

A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.